Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients.
Liwen XiongYuqing LouHao BaiRong LiJinjing XiaWentao FangJie ZhangHan Han-ZhangAnalyn LizasoBing LiAiqin GuBao-Hui HanPublished in: The Journal of international medical research (2019)
Our findings demonstrate that erlotinib is an effective neoadjuvant regimen in patients with EGFR-mutant locally advanced NSCLC, paving the way for its extended use in neoadjuvant settings.[ClinicalTrials.gov identifier: NCT01217619].